Entering text into the input field will update the search result below

Astellas to acquire Belgian drug discovery firm Ogeda for up to €800M

Apr. 02, 2017 9:41 PM ETAstellas Pharma Inc. (ALPMF) StockBy: Douglas W. House, SA News Editor8 Comments
  • Astellas Pharma (OTCPK:ALPMF)(OTCPK:ALPMY) inks an agreement to acquire Gosselies, Belgium-based clinical-stage drug discovery outfit Ogeda for up to €800M. Under the terms of the deal, Astellas will make an upfront payment of €500M for 100% of Ogeda's equity and up to €300M in milestones. The transaction should close in Q2.
  • Ogeda discovers and develops small molecule drugs targeting G-protein-coupled receptors. Its lead product candidate is Phase 2-stage fezolinetant, a selective NK3 receptor antagonist for the non-hormonal treatment of menopause-related vasomotor symptoms.

This was corrected on 06/10/2022 at 11:06 AM. Ogeda is based in Belgium.

Recommended For You

About ALPMF Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
ALPMF--
Astellas Pharma Inc.